Clinical Trials Logo

Clinical Trial Summary

This is a randomized, double-blind, controlled and multi-center Phase III clinical trial to evaluate the safety and efficacy of ASC40 tablets combined with bevacizumab in the treatment of adult patients with recurrent glioblastoma. After standard radiotherapy and chemotherapy (temozolomide), the subject first experienced clinical recurrence or progression.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05118776
Study type Interventional
Source Ascletis Pharmaceuticals Co., Ltd.
Contact Wenbin Li, Doctor
Phone 86-010-59975034
Email [email protected]
Status Not yet recruiting
Phase Phase 3
Start date November 18, 2021
Completion date September 16, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT04003649 - IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM Phase 1
Recruiting NCT04988750 - Evaluate the Safety and Preliminary Efficacy of the Combination of NaviFUS System With Re-irradiation for rGBM Patients N/A
Active, not recruiting NCT02794883 - Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma Phase 2
Completed NCT00503204 - Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour Phase 1
Active, not recruiting NCT02974621 - Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma Phase 2
Completed NCT03216499 - HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma Phase 2
Not yet recruiting NCT04717999 - Pilot Study of NKG2D CAR-T in Treating Patients With Recurrent Glioblastoma N/A
Recruiting NCT04145115 - A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioblastoma With Elevated Mutational Burden Phase 2
Recruiting NCT04044937 - Fluoroethyltyrosine in Detecting Tumors in Participants With Recurrent Intracranial Tumors Phase 2
Recruiting NCT04888611 - Neoadjuvant PD-1 Antibody Alone or Combined With DC Vaccines for Recurrent Glioblastoma Phase 2
Completed NCT00390299 - Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme Phase 1
Active, not recruiting NCT04479241 - LUMINOS-101: PVSRIPO and Pembrolizumab in Patients With Recurrent Glioblastoma Phase 2
Recruiting NCT05043701 - Individualized Systems Medicine Functional Profiling for Recurrent Glioblastoma Early Phase 1
Recruiting NCT04528680 - Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel for Recurrent Glioblastoma Phase 1/Phase 2
Active, not recruiting NCT00777153 - Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma Phase 3
Recruiting NCT04323046 - Immunotherapy (Nivolumab and Ipilimumab) Before and After Surgery for the Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults Phase 1
Recruiting NCT04440358 - Exablate Blood-Brain Barrier Disruption With Carboplatin for the Treatment of rGBM Phase 1/Phase 2
Recruiting NCT04223999 - Improving Tumor Treating Fields Treatment for Brain Cancer Patients With Skullremodeling Surgery (Neurosurgery) Phase 2
Completed NCT03022578 - Laser Interstitial Thermal Therapy and Lomustine in Treating Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma Phase 2
Recruiting NCT04417088 - Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy Phase 1/Phase 2